

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

ESG PERFORMANCE RECOGNISED BY S&P GLOBAL AND FTSE RUSSELL

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Group has been recognised by a number of authoritative global sustainability rating agencies, including S&P Global and FTSE Russell, for the Group’s sustainable and consistent performance in environmental, social and governance (ESG) practices.

In July 2024, the Group was selected as one of the 129 best performing companies in various industries in the S&P Global Sustainability Yearbook (China Edition) 2024 out of more than 1,700 companies by virtue of its outstanding performance in the S&P Global Corporate Sustainability Assessment (CSA), which is the second consecutive year for the Group to be entered in the Yearbook. CSA is one of the largest annual assessments on corporate sustainable business practices. Currently, the Group’s CSA score has steadily increased to 55 points, exceeding 92% of its global peers, and is in a world leading position.

In June 2024, the Group was selected for the first time for inclusion in the FTSE4Good Index, based on its excellent ESG practices and performance. The FTSE4Good indices series was launched in 2001 as the first series of indices designed to measure the performance of companies that meet globally recognised corporate responsibility standards. To become a constituent of the FTSE4Good Index, companies are required to implement measures across a range of corporate responsibility themes, including environmental management, climate change mitigation, anti-corruption, protection of human rights and labour rights, and labour standards in the supply chain, as well as to fulfil stringent global guidelines.

Inclusion of the Group in the FTSE4Good Index for the first time and in the S&P Global Sustainability Yearbook (China Edition) for the second consecutive year represents the continuous and high recognition of the Group's ESG practices by professional institutions in the international capital market. The Group will adhere to its original mission of "Science for a healthier world", integrate ESG concepts with its development strategy, enhance its risk management standards, promote the steady development of its business, and create long-term value for its shareholders, patients, employees and all sectors of the community.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 19 July 2024

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.